Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience by Caminati, M et al.
RESEARCH ARTICLE Open Access
Drop-out rate among patients treated with
omalizumab for severe asthma: Literature
review and real-life experience
M. Caminati1*, G. Senna1, G. Stefanizzi1, R. Bellamoli1, S. Longhi1, F. Chieco-Bianchi2, G. Guarnieri3, S. Tognella4,
M. Olivieri5, C. Micheletto6, G. Festi7, E. Bertocco8, M. Mazza9, A. Rossi7, A. Vianello2 and on behalf of North East
Omalizumab Network study group
Abstract
Background: In patients with asthma, particularly severe asthma, poor adherence to inhaled drugs negatively
affects the achievement of disease control. A better adherence rate is expected in the case of injected drugs, such
as omalizumab, as they are administered only in a hospital setting. However, adherence to omalizumab has never
been systematically investigated. The aim of this study was to review the omalizumab drop-out rate in randomized
controlled trials (RCTs) and real-life studies. A comparative analysis was performed between published data and the
Italian North East Omalizumab Network (NEONet) database.
Results: In RCTs the drop-out rate ranged from 7.1 to 19.4 %. Although the reasons for withdrawal were only
occasionally reported, patient decision and adverse events were the most frequently reported causes. In real-life
studies the drop-out rate ranged from 0 to 45.5 %. In most cases lack of efficacy was responsible for treatment
discontinuation. According to NEONet data, 32 % of treated patients dropped out, with an increasing number of
drop outs observed over time. Patient decision and lack of efficacy accounted for most treatment withdrawals.
Conclusions: Treatment adherence is particularly crucial in patients with severe asthma considering the clinical
impact of the disease and the cost of non-adherence. The risk of treatment discontinuation has to be carefully
considered both in the experimental and real-life settings. Increased knowledge regarding the main reasons for
patient withdrawal is important to improve adherence in clinical practice.
Keywords: Drop-out, Adherence, Severe asthma, Omalizumab
Abbreviations: EMA, European Medicines Agency; FEV1, Forced expiratory volume in 1 s; GETE, Global evaluation of
treatment effectiveness; IgE, Immunoglobulin E; NEONet, North East Omalizumab Network; RCT, Randomized clinical trial
Background
Adherence is usually defined as the extent to which the
patient’s use of medication matches the prescribed regimen.
Poor adherence has a critical relevance in the management
of various chronic diseases as it may negatively affect treat-
ment outcomes and result in increased hospitalizations,
morbidity, and mortality [1]. In bronchial asthma the
achievement of disease control is closely related to
adherence. It has been extensively demonstrated that
an irregular drug intake markedly affects patient’s
quality of life, as it is responsible for an increased
risk of nocturnal awakenings and impairment in rou-
tine daily activities, such as exercise and sports [2].
Lack of adherence is very common, particularly in
chronic conditions [3–7]. In fact, the treatment discon-
tinuation rate ranges from 20 to 40 % for acute illnesses
and from 30 to 60 % for chronic diseases. Preventive
treatments are associated with a non-adherence rate of
up to 80 % [8]. As far as asthma is concerned, it is well
known that about 50 % of patients are non-adherent.
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The issue becomes even more relevant in specific age
groups such as children, adolescents and elderly [9].
A number of factors, including fear of treatment-related
side effects, poor perception of symptoms, belief in
alternative/complementary medicine but also complex
treatment regimens, illness-related factors, inconvenience,
and social background, may account for poor adherence,
which has a very high social cost [1]. In the United States,
irregular drug intake among patients with hypertension is
responsible for 89 premature deaths every year [10]. It is
estimated that annually $US100 billion which is spent on
unnecessary or preventable hospitalizations related to
poor adherence could be saved [11].
Many of the above mentioned variables have been
described as determinants of poor adherence to asthma
treatments. Also, poor awareness of the need for treat-
ment even in the absence of symptoms and steroids fear
are two main reasons for treatment withdrawal in
asthmatic patients [12]. On the other side, caregivers
themselves have to face some limitations such as difficul-
ties in patients follow-up scheduling and time constraints,
which may hamper patient’s adherence support [9].
A univocal and standardized tool for evaluation of
adherence is lacking. Although many methods are
currently available none of them can be considered as
the gold standard [1]. Another controversial aspect con-
cerns the definition of “acceptable adherence”. In some
large studies, an adherence rate greater than 80 % has
been considered satisfactory [1] but a general consensus
about this issue has not been reached.
In bronchial asthma evaluation of adherence is even
more difficult as treatment is mainly based on inhaled
drugs. In this case, an objective adherence evaluation
may rely on different tools but due to many limitations
with these tools their use in routine clinical practice is
not suitable. Electronic devices are accurate but are also
quite expensive [13]; therefore recording of pharmacy
refills can be considered as a more affordable option but
they are less accurate. Patients usually deny any lack of
adherence, even in severe asthma [14].
Treatment discontinuation is one of the most relevant
aspects of adherence, as it leads to major consequences.
From this perspective, drop-out rate can be considered to
be a surrogate marker of adherence. In randomized con-
trolled trials (RCTs) a high drop-out rate can weaken the
final results [15], and in the real-life setting it is related to
preventable patient impairments and unnecessary costs.
Furthermore, the detection and quantification of drop-out
rate in a daily clinical setting is a complex issue, as regular
follow-up for all patients is not always possible. Patients
requiring treatment with injected drugs are more easily
monitored, as treatment administration requires medical
supervision. This is the case with omalizumab, an anti-
immunoglobulin E (IgE) monoclonal antibody for the
treatment of severe asthma. It must be administered in a
hospital setting once or twice a month, according to the
patient’s total IgE level [16]. Thus, treatment discontinu-
ation can be easily detected and considered as a consistent
marker of adherence.
To our knowledge, the treatment discontinuation rate
among patients undergoing omalizumab treatment has
never been systematically investigated as a primary out-
come. The present study aimed to review the drop-out
rate and describe the most common reasons for patient
withdrawal in RCTs and real-life studies published up to
December 2014. A comparative analysis between pub-
lished data and an Italian database, the North East
Omalizumab Network (NEONet), was also conducted.
Methods
Search strategy
A complete search of the Cochrane Central Register of
Controlled Trials (CENTRAL) in the Cochrane Library,
MEDLINE and PubMed up to December 2014 was
carried out. The search strategy retrieved citations con-
taining the subject heading “omalizumab” and was re-
stricted to randomized, double-blind, placebo-controlled
trials and “real life studies” for severe allergic asthma in
patients aged ≥18 years old. The keywords used were:
omalizumab, asthma, controlled studies, randomized trial,
real life studies, pragmatic studies. All retrieved studies
were restricted to the English language.
Italian North East Omalizumab Network (NEONet)
database analysis
A retrospective analysis of the NEONet database was
carried out. Details about the Network and the data
collecting methods are provided elsewhere [17]. In brief,
NEONet is a non-profit project approved by the local
ethics committee and involves 19 Allergy and Respiratory
Referral Centres for Severe Asthma located in the North-
East region of Italy. It aims to collect an extensive amount
of clinical data on patients undergoing omalizumab
treatment in a real-life setting and provide some new
insights concerning current unmet needs (e.g. impact of
omalizumab treatment on lung function and on asthma
comorbidities, long-term follow-up of treated patients,
adherence, non-responders profile, optimal treatment
duration). The participating clinicians enter anonymous
coded data into a shared limited-access web platform.
Drop-out evaluation
The drop-out rate and the most common reasons for
treatment discontinuation were evaluated, if reported, in
RCT, in “real life studies” and in the NEONet database.
Reasons for withdrawal were categorized as follows:
patient’s decision, lack of efficacy, adverse event, clinical
efficacy, and other causes. With regard to the NEONet
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database, “lack of efficacy” and “clinical efficacy” were
defined according to the GETE (global evaluation of
treatment effectiveness) Questionnaire [18], which was
completed by physicians for every patient. GETE is a
five-point scale: 1 is excellent (complete control of
asthma), 2 is good (marked improvement), 3 is moderate
(discernible, but limited improvement), 4 is poor (no ap-
preciable change), and 5 is worsening. Number 4 and 5
corresponded to “lack of efficacy” and number 1 and 2
corresponded to “clinical efficacy”.
Statistical analysis
Two-sample t-test was used to compare the variables in
Table 4. Two-proportion z-test was used to analyze the
differences between mean drop-out rates and reasons.
All tests have been performed with a significance level of
5 %. A logistic regression analysis was provided in order
to verify the association between drop-out rate and
treatment duration. R software has been used.
Results
Randomized controlled studies (RCTs)
As of December 2014, seven RCTs have been published
(Table 1) [16, 19–24]. Overall, 1719 patients were
included, with a slightly higher prevalence of females.
Across the studies, the mean age ranged from 37.5 to
43.7 years. The drop-out rate, which was reported in all
the analyzed studies, ranged from 7.1 to 19.4 %. How-
ever, reasons for withdrawal were not always reported.
Patient’s decision accounted for the majority of drop
outs in four of the selected studies [16, 20, 21, 24];
whereas in two studies adverse events were the main
cause of treatment discontinuation [19, 22]. No data
were available with regard to the timing of drop-outs
after the initiation of treatment.
Real-life studies
As of December 2014, 19 real-life studies have been
published on the use of omalizumab in severe asthma
(Table 2) [25–42]. A total of 13,466 patients were in-
cluded: compared with RCTs the age range was broader
in real-life studies (29.5 to 49.9 years) with the inclusion
of patients aged almost 10 years younger and 6 years
older than RCT patients. The mean study duration was
longer in real-life studies.
In the 13 studies that reported the drop-out rate, it
ranged from 0 to 45.5 %. No patients discontinued treat-
ment in four of these studies [27, 36, 38, 39]. There was
notable variability in the reasons given for discontinuing
treatment across the different studies. Lack of efficacy
was the most common reason for treatment discontinu-
ation in most studies [29, 34, 37, 40]. Patient decision to
discontinue treatment was the main reason for drop
outs in two studies [25, 28] and adverse events were the
most frequent reason for withdrawal in one study [37].
Comparison between RCTs and Real-life studies
Table 3 provides a direct comparison of drop-out rates
and reasons between RCTs and Real-life studies. Overall,
drop-out rate in Real-life studies is significantly higher.
The proportion of patients who discontinued omalizumab
due to a lack of efficacy was significantly bigger in real-life
studies than in RCTs. On the opposite patient’s decision
and adverse events have more relevance in RCTs in
comparison with Real-life studies.
NEONet database
The NEONet database included 221 patients. As shown
in Table 4, among them 70 (32 %) dropped out; under
treatment population and drop-outs did not significantly
differ in terms of age, gender and mean treatment dur-
ation. Treatment discontinuation was more common
amongst females (64 %). Patient decision accounted for
most of the withdrawals (49 %), followed by a lack of
efficacy (26 %). Within the group of patients dropping-
out for “onset of contraindications”, pregnancy was the
reason in all the cases. As far as adverse events is
concerned, 3 cases of generalized urticarial have been
described; arthralgia and myocarditis have been recorded
in two other cases.
Table 5 provides a comparative overview of NEONet
database and published Real-life studies in terms of
Table 1 Overall dropout rate and main reasons for treatment discontinuation in RCT
Author [ref] N duration
(months)
Mean ± SD
age, years
M/F
Ratio
Drop-out
rate (%)
Patient
decision (%)
Lack of
efficacy (%)
Adverse
events (%)
Other
Causes (%)
Busse et al. 2001 [16] 268 7 39.3 0.63 7.1 4.1 0.37 0.74 1.49
Soler et al. 2011 [23] 274 7 40.0 1.06 6.9 1.09 1.09 NR NR
Holgate et al. 2004 [21] 126 8 41.1 0.55 8.7 8.7 NR NR NR
Ayres et al. 2004 [19] 206 12 37.5 0.39 7.3 NR NR 7.3 NR
Vignola et al. 2004 [24] 209 7 38.3 ± 14.7 0.92 8.1 8.1 NR NR NR
Humbert et al 2005 [22] 209 7 43.4 ± 13.3 0.48 12.2 NR NR 4.5 NR
Hanania et al. 2011 [20] 427 12 43.7 ± 14.3 0.63 19.4 11.00 NR 3.74 4.68
F female, M male, NR not reported, RCT randomized controlled trials, SD standard deviation
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drop-out rates and reasons. The overall drop-out rate
was significantly higher in NEONet database. Patient’s
decision as a cause of dropping out showed the same
trend. On the opposite drop-out rates due to lack of
efficacy and adverse events do not significantly differ
between NEONet and published Real-life studies.
In our study population the proportion of drop-outs
does not significantly change in different treatment dur-
ation time intervals, as described in Fig. 1, which also
shows the 95 % Confidence Interval (CI) (blue lines). Fur-
thermore, the logistic regression analysis confirms the lack
of association between time and drop-out rate (p = 0.96).
Discussion
This review of publications on omalizumab in severe
asthma demonstrated that there is a wide variability in
both the drop-out rate and the reasons for discontinuing
treatment. Drop-out rates appeared to be the lowest in
RCTs—possibly because these studies are conducted
under rigorously controlled conditions. In contrast, real-
life studies, which are more closely aligned with routine
clinical practice, cited markedly higher drop-out rates of
up to 46 %. The NEONet database was more in line with
the data from real-life studies with reported dropout
rates of 32 %. Lack of efficacy was cited as one of the
most common reasons for treatment discontinuation in
both real-life studies and the NEONet database, while
patient decision and adverse events primarily contrib-
uted to the drop-out rates observed in RCTs.
Poor treatment adherence is a well-known unmet need
in patients with asthma. This is particularly the case
with inhaled drugs [2, 13, 43]. Data regarding adherence
patterns in patients treated with omalizumab are limited
and the evidence is weakened by methodological differ-
ences across the studies [44]. However, despite the
reported drop-out rates, adherence to omalizumab
Table 2 Overall dropout rate and main reasons for treatment discontinuation in real-life studies
Author [ref] N duration
(months)
Mean ± SD
age, years
M/F
Ratio
Drop-out
rate (%)
Patient
decision (%)
Lack of
efficacy (%)
Adverse
events (%)
Other
Causes (%)
Molimard et al. 2008 [37] 146 12 46.5 ± 13.5 0.57 30.6 1.4 19 5.4 4.8
Brusselle et al. 2009 [29] 158 12 48.1 ± 17.1 0.85 45.5 10.1 13.3 12 10.1
Korn et al. 2009 [34] 280 5 43.9 ± 16.3 1.45 32.5 NR 14.28 NR NR
Bavbek et al. 2010 [27] 18 6 41.8 ± 11.2 0.63 0 NR NR NR NR
Cazzola et al. 2010 [30] 142 24 49.6 ± 4.1 1 8.5 2.11 1.4 1.4 3.5
Tzortzaki et al. 2012 [39] 60 26 54.0 ± 14.0 0.66 0 NR NR NR NR
Wittchen et al. 2012 [42] 53 24 48.3 ± 13.7 1 NR NR NR NR NR
Vennera M et al. 2012 [40] 266 15 51.0 ± 13.7 0.45 18.7 5.6 10.5 2.6 NR
Lafeuille et al. 2012 [35] 644 24 49.9 ± 14.2 0.69 NR NR NR NR NR
Eisner et al. 2012 [32] 4969 12 44.5 ± 16.6 0.56 NR NR NR NR NR
Chen et al. 2013 [31] 4970 48 44.5 ± 16.6 0.56 NR NR NR NR NR
Grimaldi-Bensouda et al. 2013 [33] 374 36 49.7 ± 14.6 0.58 NR NR NR NR NR
Barnes et al. 2013 [26] 136 36 41.3 ± 14.5 0.46 NR NR NR NR NR
Maselli et al. 2013 [36] 26 6 29.6 ± 18.7 1.6 0 NR NR NR NR
Group 1a
Maselli et al. 2013 [36] 26 24 34.0 ± 17.6 NR 0 NR NR NR NR
Group 2b
Braunstahl et al. 2013 [28] 943 12 45.0 ± 15.5 NR 16.6 8.4 NR NR 8.2
Özgür et al. 2013 [38] 26 6 47.6 ± 13.9 0.23 0 NR NR NR NR
Vieira et al. 2014 [41] 15 6 45.6 ± 10.8 0.15 26.66 6.66 NR 20.00 NR
Ancochea et al. 2014 [25] 214 12 48.2 ± 17.7 0.43 7.9 4.2 2.3 1.9 NR
F female, M male, NR not reported, RCT randomized controlled trials, SD standard deviation
aPatients with IgE levels above 700 IU/mL
bPatients with IgE levels less or equal to 700 IU/mL
Table 3 Comparison of drop-out rate mean values and reasons
between RCTs and Real-life studies
RCT Real-life p-value
Drop-out 11.65 % 17.50 % 0.0000
Patient decision 59.72 % 35.01 % 0.0000
Lack of efficacy 0.69 % 23.53 % 0.0000
Adverse events 22.92 % 12.04 % 0.0011
Other causes 116.67 % 29.41 % 0.0016
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appears to be slightly higher than that observed with
other anti-asthmatic drugs [45, 46]. Therefore, omalizumab
therapy has been proposed as an alternative for patients
with poorly controlled asthma for whom adherence does
not improve with conventional interventions [46]. One pos-
sible explanation is that compared with oral or inhaled
treatments, omalizumab is regularly administered in a
hospital setting under direct medical supervision thereby
improving treatment adherence. Conversely, subcutaneous
allergen immunotherapy, which is also regularly adminis-
tered in a hospital setting to patients with respiratory
allergy [47], is characterized by a lower adherence rate in
comparison to omalizumab [6, 48]. Of note, this immuno-
therapy is indicated in mild to moderate asthmatics with
less severe symptoms [47]. On this basis, it could be argued
that disease severity can positively affect adherence to treat-
ment. A non-adherence rate of 44 % in asthmatics with
steroid-dependent asthma has been reported [14]. Further-
more, a recent observational study on omalizumab adher-
ence identified a lower pre-bronchodilator percentage of
predicted forced expiratory volume in 1 s (FEV1) as an
independent predictor of good adherence [44].
Treatment discontinuation unrelated to medical reasons
represents the major drawback of non-adherence. It
implies there are preventable direct and indirect costs
affecting both patient quality of life and health systems
resources [49]. To the best of the authors’ knowledge the
drop-out rate among patients undergoing omalizumab
treatment has never been systematically investigated as a
primary outcome.
Overall, a lower rate of treatment discontinuation with
a narrow range was observed in RCTs. This finding is to
be expected if the setting of experimental studies is
taken into account. In fact, the RCT protocol typically
mandates regular patient assessment and a strict follow-
up schedule, often with a shorter duration of follow-up
in comparison with real-life studies. All of these factors
may account for a lower withdrawal rate, which is also a
methodological requirement in order to strengthen the
final results [15, 50]. Surprisingly, the reasons for patient
drop outs were not reported in some RCTs [21, 24].
However, adverse effects and patient decision were
responsible for most drop outs across the reviewed
studies [25, 28, 29, 34, 37, 40]. RCT protocols are usually
demanding for patients and withdrawal due to incon-
venience is not unexpected [48]. As far as adverse effects
are concerned, RCT protocols include strict and careful
monitoring of potential treatment-related adverse events
that more frequently results in patient exclusion from
the study than in the real-life setting [50, 51].
In the real-life studies, drop-out prevalence was
characterized by a marked variability, ranging from 0 %
in four studies up to 45 % in the remaining studies.
Although the reasons for drop-outs were sporadically
reported, in most cases lack of efficacy was responsible
for treatment discontinuation. The proportion of
patients who discontinued omalizumab due to a lack of
efficacy was significantly higher in real-life studies than
in RCTs. The different patient selection process may
provide a possible explanation. In fact, patients’ enrol-
ment in RCTs relies on strict inclusion and exclusion
criteria, which differs from the real-life setting.
A recent review from our group [51] has highlighted
that sensitization to a perennial allergen is missing in
Table 4 Overall drop-out rate and main reasons for treatment discontinuation in the NEONet database
Patient population (n = 221) Drop-out patients (70, 32 %) Patients under treatment (151, 38 %) p-value
Males, n (%) 25 (35.71) 68 (45.03) 0.0959
Females, n (%) 45 (64.29) 83 (54.97)
Age-years, mean (SD) 46.79 (14.82) 47.44 (13.11) 0.4904
Treatment duration-months, mean (SD) 27.69 (20.94) 27.54 (22.96) 0.4992
Reason for drop-out, n (%)
Lack of efficacy 18 (26)
Patient’s decision discontinuation 34 (49)
Efficacy 4 (6)
Adverse events (local or systemic reactions) 5 (7)
Onset of contraindications 6 (8)
Patient moved to another referral center 3 (4)
NEONet North East Omalizumab Network, SD standard deviation
Table 5 Comparison of drop-out rate mean values and reasons
between NEONet database and published Real-life studies
NEONet Real-life p-value
Drop-out 31.67 % 17.50 % 0.0000
Patient decision 48.57 % 35.01 % 0.0160
Lack of efficacy 25.71 % 23.53 % 0.3475
Adverse events 7.14 % 12.04 % 0.1176
Other causes 18.57 % 29.41 % 0.0318
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more than 20 % of patients undergoing omalizumab
treatment, despite being included among the prescrip-
tion criteria established by the European Medicines
Agency (EMA) [52]. However, non-responders have also
been described among patients matching all the EMA
prescription criteria [17, 28], and the efficacy of omalizu-
mab in non-atopic asthma is also supported by the lit-
erature [53]. Patient selection, particularly in the field of
biological drugs for asthma, still represents a challenge
[54, 55]. The relevance of a number of biomarkers has
been recently investigated and still fosters current
research. The poor specificity of many molecules and
the complex relationship between symptoms, exacerba-
tions, response to drugs and underlying inflammation
hampers the identification of univocal and standardized
biomarkers predictive of clinical response [56, 57]. Such
biomarkers are still lacking for omalizumab and for
current and upcoming biological treatments for severe
asthma [55, 58].
Nevertheless, patient selection is one of the most
important aspects in managing biological drugs as they
target a very specific mechanism in the pathophysiologic
picture of the disease [58, 59].
Omalizumab has a good safety profile, both in the
experimental and real-life setting. Only three studies,
two RCTs [19, 22] and one real-life study [37], reported
adverse events as the main cause of treatment discon-
tinuation, without any significant differences in terms of
drop-out rate. Of note, a local reaction at the injection
site was the commonest adverse event. This finding
suggests that tolerability is an important issue and con-
sequently it has to be carefully considered; as evidenced
with other treatments, it can significantly affect adherence
[60]. Therefore, clinicians should discuss tolerability
issues with their patients as part of a strategy aimed
at improving adherence.
The results from the NEONet database were similar to
those reported in published studies, although the overall
drop-out rate seems to be higher in our study population.
For project’s policy, Referral Centers included in the
NEONet collaboration are requested to strictly and regu-
larly follow-up the patients, thus under this perspective
our clinical practice is more similar to a RCT setting than
to a pure real-life one. It may provide an explanation for
our finding. However drop-out rates due to lack of efficacy
and adverse events do not significantly differ between
NEONet and published Real-life studies. The population
sample was smaller in comparison with other real-life
studies, however it is quite homogeneous, as the patients
live in the same geographical area, and the centers share
the same diagnostic work-up and patient selection criteria
[17]. In the NEONet population, patient decision was the
most common reason for dropping out. Although several
reasons can influence patient choice, inconvenience may
play the most relevant role [6, 14]. In fact, the need for
regular administration of omalizumab in hospital once or
twice per month can strongly affect treatment adherence,
as it has many implications such as work-absenteeism and
economic burden. Under this perspective, patient’s per-
ception of clinical efficacy as well as lack of efficacy, has a
crucial relevance as it may weaken the motivation of the
patient for continuing treatment.
Interestingly, in our study population treatment length
does not seem to affect drop-out rate. In fact, the
proportion of drop-outs is similar in all the treatment
duration time intervals (Fig. 1). Apparently the drop-out
rate in the last interval is higher, but the small sample
size in that range may account for this effect, as shown
in the graph by the CI bars. Furthermore, the logistic
regression analysis confirms the lack of association
between time and drop-out rate (p = 0.96). Whether the
length of treatment impacts on the adherence rate is not
Fig. 1 Drop-out rates in different treatment duration time intervals (NEONet database; n= 221). The blue lines indicate the 95 % Confidence Interval (CI)
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easy to evaluate in the published studies, due to the
great variability in terms of study duration [25–42].
However the ideal treatment duration, as well as the
identification of biomarkers that are accurate in predict-
ing the clinical response are still lacking [58, 59]. In fact,
lack of efficacy, similarly to the published Real life studies
[25–42], accounted for 26 % of drop-outs among NEONet
patients, despite all patients being fully matched with the
current prescription criteria. In the real-life setting, many
patient-related variables, such as smoking habits, comor-
bidities, and multi-drug treatments, may affect treatment
efficacy and effectiveness [51, 61], even though
prescription criteria are verified. In this scenario
patient’s education, in terms of awareness of the treat-
ment and its implications, has an even more relevant
role in preventing drop-outs and generally supporting
adherence [62, 63].
Some limitations of our work deserve to be highlighted.
Two variables potentially affecting the drop-out rate, lung
function at baseline and prescribed medications other
than Omalizumab, have not been extensively analyzed. In
the case of the first determinant, few data are available in
literature, however a lower forced expiratory volume in
1 s (FEV1) has been described as an independent predictor
of good adherence [44]. Concerning the published studies
included in the present review [16, 19–42], a systematic
analysis of the lung function and its impact on drop-out
rate is not easy relying on the available information,
affected by great variability, or not mentioned at all. In
our dataset analysis, GETE questionnaire for the evalu-
ation of clinical efficacy indirectly includes the impact of
treatment on lung function. As lack of efficacy is one of
the main drop-out reasons, it could be hypothesized that a
poor lung function at baseline, maintained during the
treatment, may act as a determinant of poor adherence.
A great variability, or the lack of detailed information,
also regards the prescribed medications other than
Omalizumab [16, 19–42] and hampers an extensive
analysis of this further drop-out determinant. The
scenario is even more complex if we consider the
amount of drugs prescribed for comorbidities. Such ana-
lysis is out of the aim of our paper and requires an
adequately sized population sample. However, according
to the literature adherence to omalizumab appears to be
slightly higher than that observed with other anti-
asthmatic drugs, independently of other medication
prescribed at the same time [45, 46].
A second limitation of our work relates to the
study design itself; in real-life observational studies
it is difficult to avoid or properly assess bias, and
conclusions are not easily applicable across a gener-
alized population. Furthermore, often only a descrip-
tive analysis has been provided. Nevertheless, to our
knowledge treatment discontinuation rate has never
been systematically investigated as a primary out-
come in a real-life setting and awareness of the most
common reasons for patient withdrawal may help in
finalizing some practical suggestions to improve
adherence in routine clinical practice.
Conclusion
In conclusion, the risk of treatment discontinuation is a
significant drawback for omalizumab therapy and this
warrants consideration when prescribing. The reasons
for dropping out have to be carefully taken into consid-
eration when planning specific long-term strategies in
order to prevent treatment withdrawal.
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